In this 2-part activity, experts in the treatment of neurodegenerative disorders discuss the latest information pertaining to the management of Alzheimer’s disease and Huntington’s disease. They provide a succinct overview of the pathophysiology and current therapeutic options for these diseases, explore potential cellular targets for the development of novel therapies, and examine recent clinical data pertaining to these therapies.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of neurologists and other clinicians involved in the management of patients with Alzheimer’s disease and Huntington’s disease.
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
The School of Medicine at the University of Alabama at Birmingham, UAB, is committed to the provision of CME that is balanced, objective, and evidence based. UAB adheres to Accreditation Council for Continuing Medical Education (ACCME) Essentials and Standards. Accordingly, all parties involved in content development have disclosed any real or apparent financial relationships relating to the topics of this educational activity and the disclosure summary follows. UAB has established mechanisms to resolve conflicts of interest should they arise. Participants in UAB CME programs are afforded the opportunity to provide feedback on the quality of individual programs. Comments can also be sent directly to the Division of CME at (cme@uab.edu).
Rachelle S. Doody, MD, PhD Professor of Neurology Effie Marie Cain Chair in Alzheimer's Disease Research Director, Alzheimer's Disease and Memory Disorders Center Baylor College of Medicine Houston, Texas
Rachelle S. Doody, MD, PhD, has a financial interest/relationship or affiliation in the form of: Consultant for Allon Therapeutics Inc.; Astellas Pharma US, Inc.; Dainippon Sumitomo Pharma Co., Ltd.; GlaxoSmithKline; Medivation, Inc.; Noven Pharmaceuticals, Inc.; Ocera Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc; Schering-Plough Corporation; Sonexa Therapeutics, Inc.; Suven Life Sciences Limited; Transition Therapeutics Inc.; and Varinel, Inc.Grant/Research Support from Elan Pharmaceuticals, Inc.; Janssen, L.P.; Pfizer Inc; and Wyeth Pharmaceuticals Inc.Advisory Board for Data and Safety Monitoring Board (DSMB) for GlaxoSmithKline; Medivation, Inc.; and Sonexa Therapeutics, Inc.
Ray Dorsey, MD, MBA Assistant Professor Department of Neurology University of Rochester School of Medicine and Dentistry Rochester, New York
Ray Dorsey, MD, MBA, has a financial interest/relationship or affiliation in the form of: Consultant for Lundbeck Research USA, Inc.Grant/Research Support from Lundbeck Research USA, Inc.; Medivation, Inc.; and Pfizer Inc.Advisory Board for Lundbeck Research USA, Inc.Other Financial or Material Support from stock options in Avid Radiopharmaceuticals, Inc.
Khurram Bashir, MD, MPH Associate Professor of Neurology Department of Neurology University of Alabama at Birmingham Birmingham, Alabama
Khurram Bashir, MD, MPH, currently has no financial interests/relationships or affiliations in relation to this activity.
Kirk A. Tacka, PhD PVI, PeerView Institute for Medical Education, Inc.
Kirk A. Tacka, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Alabama School of Medicine and PVI, PeerView Institute for Medical Education. The University of Alabama School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Alabama School of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The University of Alabama School of Medicine is an equal opportunity/affirmative action institution.
This CME activity is jointly sponsored by the School of Medicine at the University of Alabama at Birmingham and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
All contents copyright © 2000-, PeerView Press. All rights reserved.
